Presentation is loading. Please wait.

Presentation is loading. Please wait.

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase.

Published byIivari Saaristo Modified over 5 years ago

Similar presentations

Presentation on theme: "Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase."— Presentation transcript:

1 Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial by Mikkel Z. Oestergaard, Christopher Bolen, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Alexandar Tzankov, Umberto Vitolo, Tina Nielsen, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, and Georg Lenz Blood Volume 130(Suppl 1): December 7, 2017 ©2017 by American Society of Hematology

2 Mikkel Z. Oestergaard et al. Blood 2017;130:1543
©2017 by American Society of Hematology

Download ppt "Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase."

Similar presentations

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Long-term outcome of patients in the LNH-98

Long-term outcome of patients in the LNH-98
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):3102-3111.

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis by Katharine H.

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis by Katharine H.
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.
Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma by Florian Scherer, David M. Kurtz, Aaron M. Newman, Henning.

Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma by Florian Scherer, David M. Kurtz, Aaron M. Newman, Henning.
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma by Anamarija M. Perry, Teresa.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma by Anamarija M. Perry, Teresa.
EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):328-340.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy by Fabian Zohren, Ingmar.

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy by Fabian Zohren, Ingmar.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.
Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma by Raija Ristamäki, Heikki Joensuu, Kimmo Lappalainen, Lasse.

Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma by Raija Ristamäki, Heikki Joensuu, Kimmo Lappalainen, Lasse.
Alternate designs for conduct and analysis of phase I cancer trials

Alternate designs for conduct and analysis of phase I cancer trials
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
TCR-MHC-peptide(s): in vivo veritas

TCR-MHC-peptide(s): in vivo veritas

Similar presentations

Ads by Google